ASCO 2021: Rongchang Bio-ADC's new drug Vidicuzumab once again appeared at the conference, showing blockbuster clinical data!

On June 4, 2021 (Eastern Time), the 57th annual meeting of the American Society of Clinical Oncology ( ASCO ) opened.

On June 4, 2021 (Eastern Time), the 57th annual meeting of the American Society of Clinical Oncology ( ASCO ) opened.

The annual ASCO annual meeting brings together the world's top oncology experts and well-known pharmaceutical companies, research institutions and investment institutions.

At this ASCO annual meeting, a single-arm, multi-center phase II clinical study of vedicitumumab for locally advanced or metastatic urothelial carcinoma with HER2 overexpression led by Professor Guo Jun from Peking University Cancer Hospital was released.

Also led by Professor Guo Jun from Peking University Cancer Hospital and Professor Sheng Xinan in charge of vedicitumumab combined with PD-1 antibody teriprizumab for the preliminary Ib/II phase study of locally advanced or metastatic urothelial carcinoma The results were also reported for the first time at the meeting.

Before the results of the above two clinical studies were released, the indication for urothelial carcinoma of vedicitumumab was based on the world’s leading clinical data, and it has been dually recognized by the US FDA and China’s National Food and Drug Administration as a breakthrough therapy.

In addition to new breakthroughs in the field of urothelial cancer, Vidicuzumab has also obtained exciting data in the exploration of the clinical value of breast cancer.

The summary analysis of "Phase I and 1b studies of vedicitumumab in the treatment of HER2-positive and HER2 low-expressing breast cancer" led by Professor Xu Binghe from the Cancer Hospital of the Chinese Academy of Medical Sciences and Professor Wang Jiayu, shines with excellent efficacy data This ASCO conference.

 

 

 

 

An antibody-drug conjugate targeting HER2, RC48, was used in the combined analysis of two studies of advanced or metastatic breast cancer patients with HER2 positive and HER2 low expression.

 

RC48-ADC, a HER2-targeting antibody-drugconjugate, in patients with HER2-positive and HER2-low expressing advanced ormetastatic breast cancer: A pooled analysis of two studies

【Abstract Number】 #1022

【Abstract Number】【Abstract Number】#1022

【Exhibition form】 Discussion in the poster

【Exhibition form】【Exhibition form】Poster discussion

[Researcher] Xu Binghe and Wang Jiayu

[Researcher] [Researcher] Xu Binghe and Wang Jiayu

[Core Points]RC48 is used for the pooled analysis of two studies of advanced or metastatic breast cancer patients with HER2 positive (IHC 3+, or IHC 2+/FISH+) and HER2 low expression (IHC 2+/FISH-, or IHC 1+).

[Key Points] [Key Points]RC48 is used for the pooled analysis of two studies of advanced or metastatic breast cancer patients with HER2 positive (IHC 3+, or IHC 2+/FISH+) and HER2 low expression (IHC 2+/FISH-, or IHC 1+).

 

RC48 is used in a single-arm multicenter phase II clinical study of HER2 overexpression locally advanced or metastatic urothelial carcinoma.

An Open-label, Single-arm, Multicenter,Phase II Study of RC48 to Evaluate the Efficacy and Safety of Subjects withHER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer(RC48-C009)

【Abstract Number】 #4584

【Abstract Number】【Abstract Number】#4584

[Display form] Poster display

[Display form] [Display form] Poster display

[Researcher] Guo Junsheng Xinan

[Researcher] [Researcher] Guo Junsheng Xinan

[Key points] RC48 is used in a single-arm multicenter phase II clinical study of HER2 overexpression locally advanced or metastatic urothelial carcinoma.

[Core Points] [Core Points] As of March 2021, the objective effective rate of independent imaging assessment reached 50%, the median progression-free survival time was 5.

 

 

 

 

Combination of RC48 and teriprizumab in the treatment of locally advanced or metastatic urothelial carcinoma (UC): preliminary results of a phase Ib/II study

Combination of RC48 and teriprizumab in the treatment of locally advanced or metastatic urothelial carcinoma (UC): preliminary results of a phase Ib/II study

 

Preliminary results of RC48 combinedwith toripalimab in patients with locally advanced or metastatic urothelialcarcinoma (RC48-C014)

Preliminary results of RC48 combinedwith toripalimab in patients with locally advanced or metastatic urothelialcarcinoma (RC48-C014)

【Abstract Number 】 #4534

【Abstract Number【Abstract Number 】】

[Display form] Poster display

【Exhibition form】【Exhibition form】

[Researcher] Sheng Xinan and Zhou Li

[Researcher] [Researcher]

[Core points] RC48 combined with teriprizumab for locally advanced or metastatic urothelial cancer phase Ib/II clinical study preliminary results: this is a teriprizumab combined with RC48 for at least the first line in the past Treatment failure or intolerance/unwillingness to receive cisplatin chemotherapy for metastatic urothelial cancer.

[Core Points] [Core Points] The results showed that the ORR reached 94.

■ ■ About Vidicuzumab About Vidicuzumab

Vidicituzumab is an original antibody conjugate (ADC) new drug independently developed by Rongchang Biological.
ADC drugs are conjugated with monoclonal antibodies, linkers, and small molecule cytotoxic drugs, which can perform precise strikes on cancer cells like a missile .
Different from similar foreign drugs, the antibody component of vedicitumumab is a brand-new drug with differentiated biological properties.
Therefore, it can target HER2 protein on the tumor surface to accurately identify cancer cells, penetrate cell membranes and use Small-molecule cytotoxic drugs kill them, and have better targeting, higher efficacy and better drug resistance.

Precise

Clinical data shows that the clinical trials of vedicitumumab in the treatment of HER2-expressing gastric cancer and urothelial cancer with ADC drugs are leading the world, and several studies in the field of breast cancer are underway, filling many gaps at home and abroad.
.
In August 2020, the listing application for gastric cancer indications submitted to the State Food and Drug Administration was given priority review and is expected to be approved for listing soon.
Internationally, vedicitumumab urothelial carcinoma indications have been certified as a dual breakthrough therapy by the National Food and Drug Administration and the US FDA.

Leave a message here